PUR-5700 / Pulmatrix - LARVOL DELTA

Ex-vivo Evaluation of the Potential for Narrow Spectrum Kinase Inhibitors as a Treatment for Idiopathic Pulmonary Fibrosis (ATS 2024) - "PCLS core samples in duplicate were treated with test compounds RV1162, RV7031, Nintedanib as a positive control or vehicle as a negative control. Similarly, RV7031 resulted in a dose-related reduction in IL-6 only. These data indicate that Narrow Spectrum Kinase Inhibitors in general, and RV1162 in particular, reduce endogenous pro-inflammatory cytokine production and IPF-related gene expression in lung tissue samples from IPF donors and accordingly may have potential for the treatment of IPF."

Preclinical • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases • IL6 • MMP9 • SYK